Aldara(TM) (Imiquimod) Cream, 5% Included in More Than 20 Presentations at American Academy of Dermatology's 64th Annual Meeting

3M (NYSE:MMM):

-- Aldara is the First and Only Immune Response Modifier Indicated for the Treatment of Actinic Keratosis, Superficial Basal Cell Carcinoma and External Genital Warts

3M announced today that Aldara Cream is a featured topic in more than 20 presentations by leading researchers at the upcoming American Academy of Dermatology's (AAD) 64th annual meeting in San Francisco, March 3-7. Aldara Cream is the first and only immune response modifier indicated for the treatment of precancerous actinic keratosis, superficial basal cell carcinoma and external genital and perianal warts. The prescription therapy works by stimulating the skin's immune response to clear diseased or damaged cells.

"Dermatologists have come to recognize Aldara Cream as an important innovation in the treatment of actinic keratosis, external genital warts and basal cell carcinoma," said John Sampson, vice president, 3M Pharmaceuticals Division. "Aldara Cream's strong presence at the AAD annual meeting highlights dermatologists' recognition of the drug's unique mechanism of action, which engages the body's own immune system to fight these major skin conditions."

Aldara posters can be viewed in San Francisco's Moscone Center Hall A on:

-- Friday, March 3 (1 p.m. to 7 p.m.)

-- Saturday, March 4 and Sunday, March 5 (7 a.m. to 7 p.m.)

-- Monday, March 6 (7 a.m. to 5:30 p.m.)

Presenters will be at their posters from 12 p.m. to 2 p.m. on Saturday (even numbered posters) and Sunday (odd numbered posters). In addition to the poster presentations noted below, Aldara Cream also will be discussed during several ticketed symposia at the AAD annual meeting.

Aldara Cream Presentations
Saturday March 4, 2006, 12 p.m. to 2 p.m.: Poster Viewing Session, Hall A

-- Multicenter, Open-Label Study Using Imiquimod 5% Cream In 1 or 2 Four-Week Courses of Treatment for Multiple Actinic Keratoses on the Head. E. Stockfleth, MD, PhD. Poster 580.

-- Imiquimod 5% Cream Improves the Appearance and Structure of Photoaged Skin. A. Kligman, MD, PhD. Poster 1138.

-- Imiquimod 5% Cream in the Treatment of Chronic tinea Pedis Interdigitalis: A Proof-of-Concept Pilot Study. V. Baliga, PhD. Poster 1918.

-- Neoadjuvant Therapy with 5% Imiquimod Cream Previous to Mohs Micrographic Surgery for the Treatment of Basal Cell Carcinoma. E. Nagore, MD. Poster 2406.

-- Effectiveness of Curettage and 5% Imiquimod Cream in the Treatment of Basal Cell Carcinoma: Clinical and Cosmetic Evaluation. D. Rigel, MD. Poster 2420.

-- A Double-Blind, Prospective Study Evaluating the Tolerability of Application of Imiquimod 5% Cream vs. Vehicle Cream to Keloid Shave Excision Sites. B. Berman, MD. Poster 3206.

Sunday March 5, 2006, 12 p.m. - 2 p.m.: Poster Viewing Session, Hall A

-- Imiquimod as an Antiaging Agent. S. Metcalf, MD. Poster 1139.

-- Assessment of Efficacy, Safety and Tolerability of Imiquimod cream 5% in Adult Patients with External Genital Warts: A First Indian Study. A. Desai, MD. Poster 1703.

-- An Investigator-Blinded Assessment Comparing the Tolerability of Imiquimod 5% Cream and Topical 5-Fluororouracil Cream in the Treatment of AK. J. Del Rosso, DO. Poster 2417.

-- Non-Viral Uses of Imiquimod. A. Gupta, MD. Poster 2423.

-- Topical Imiquimod as an Adjuvant to Laser Tattoo Removal in the Guinea Pig. M. Ramirez, MD. Poster 3305.

(Aldara Cream is indicated for actinic keratosis, superficial basal cell carcinoma, and external genital and perianal warts. As with all scientific meetings, results of studies that include investigational uses of drugs may be presented.)

About Aldara Cream

Aldara Cream is a topical (skin-use only) prescription medicine and is the first and only immune response modifier (IRM) approved to treat three skin conditions: actinic keratosis, a precancerous skin condition, superficial basal cell carcinoma, a form of skin cancer, and external genital and perianal warts, caused by the Human Papillomavirus, or HPV. Aldara stimulates the body's own defense mechanism to identify and clear diseased and damaged cells. When using Aldara Cream, the most common side effects involved skin reactions in the application area. These included redness, swelling, erosions, induration, weeping, scabbing/crusting, flaking/scaling, itching and burning. Exposure to sunlight (including sunlamps) should be avoided or minimized during use of Aldara Cream for actinic keratosis or superficial basal cell carcinoma because of concern for heightened sunburn susceptibility. Patients should be warned to use protective clothing (hat) when using Aldara Cream.

For full prescribing information see www.Aldara.com

About 3M Pharmaceuticals - Part of the 3M Health Care Family

3M Health Care is dedicated to improving the practice, delivery and outcome of care in medical, dental, pharmaceutical, health information and personal care markets. 3M Pharmaceuticals, part of the 3M Health Care family, develops, manufactures and sells branded prescription drug products for dermatology, women's health, sexual health, cardiology and respiratory medicine. More information about Aldara Cream is available at www.aldara.com.

About 3M - A Global, Diversified Technology Company

Every day, 3M people find new ways to make amazing things happen. Wherever they are, whatever they do, the company's customers know they can rely on 3M to help make their lives better. 3M's brands include Aldara, Scotch, Post-it, Scotchgard, Thinsulate, Scotch-Brite, Filtrete, Command and Vikuiti. Serving customers in more than 200 countries around the world, the company's 69,000 people use their expertise, technologies and global strength to lead in major markets including consumer and office; display and graphics; electronics and telecommunications; safety, security and protection services; health care; industrial and transportation. For more information, including the latest product and technology news, visit www.3M.com.

Aldara, Scotch, Post-it, Scotchgard, Thinsulate, Scotch-Brite, Filtrete, Command and Vikuiti are trademarks of 3M.

3M, St. PaulHala Mirza, 917-929-1734orEmily Faucette, 415-595-9407orGlenn Carter, 612-802-8306

Other Topics

Contact Media Relations

Contact Media Email
 

Media Hotline: 651-733-8805
 

These contacts are intended only for the media. If you are not a member of the media, please call 1-888-3M HELPS (1-888-364-3577).
 

We will get back to you within one business day.

Email Alerts

Subscribe to receive automatic updates via email for 3M news & stories.

Subscribe